<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>8</volume><submitter>Molinero M</submitter><pubmed_abstract>&lt;h4>Background&lt;/h4>The pathophysiology of COVID-19-related critical illness is not completely understood. Here, we analyzed the microRNA (miRNA) profile of bronchial aspirate (BAS) samples from COVID-19 and non-COVID-19 patients admitted to the ICU to identify prognostic biomarkers of fatal outcomes and to define molecular pathways involved in the disease and adverse events.&lt;h4>Methods&lt;/h4>Two patient populations were included (&lt;i>n&lt;/i> = 89): (i) a study population composed of critically ill COVID-19 and non-COVID-19 patients; (ii) a prospective study cohort composed of COVID-19 survivors and non-survivors among patients assisted by invasive mechanical ventilation (IMV). BAS samples were obtained by bronchoaspiration during the ICU stay. The miRNA profile was analyzed using RT-qPCR. Detai</pubmed_abstract><journal>Frontiers in medicine</journal><pagination>756517</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8850692</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Bronchial Aspirate-Based Profiling Identifies MicroRNA Signatures Associated With COVID-19 and Fatal Disease in Critically Ill Patients.</pubmed_title><pmcid>PMC8850692</pmcid><pubmed_authors>Penuelas O</pubmed_authors><pubmed_authors>Gort-Paniello C</pubmed_authors><pubmed_authors>de Gonzalo-Calvo D</pubmed_authors><pubmed_authors>Torres G</pubmed_authors><pubmed_authors>Cabo R</pubmed_authors><pubmed_authors>Fernandez-Barat L</pubmed_authors><pubmed_authors>Garcia-Gasulla D</pubmed_authors><pubmed_authors>Benitez ID</pubmed_authors><pubmed_authors>Bermejo-Martin JF</pubmed_authors><pubmed_authors>Barbe F</pubmed_authors><pubmed_authors>Molinero M</pubmed_authors><pubmed_authors>Vengoechea JJ</pubmed_authors><pubmed_authors>Moncusi-Moix A</pubmed_authors><pubmed_authors>Caballero J</pubmed_authors><pubmed_authors>Gonzalez J</pubmed_authors><pubmed_authors>Motos A</pubmed_authors><pubmed_authors>Riera J</pubmed_authors><pubmed_authors>Ferrer R</pubmed_authors><pubmed_authors>Gomez S</pubmed_authors><pubmed_authors>Rodriguez-Jara F</pubmed_authors><pubmed_authors>Garcia-Hidalgo MC</pubmed_authors><pubmed_authors>Ceccato A</pubmed_authors><pubmed_authors>Torres A</pubmed_authors><pubmed_authors>Menendez R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Bronchial Aspirate-Based Profiling Identifies MicroRNA Signatures Associated With COVID-19 and Fatal Disease in Critically Ill Patients.</name><description>&lt;h4>Background&lt;/h4>The pathophysiology of COVID-19-related critical illness is not completely understood. Here, we analyzed the microRNA (miRNA) profile of bronchial aspirate (BAS) samples from COVID-19 and non-COVID-19 patients admitted to the ICU to identify prognostic biomarkers of fatal outcomes and to define molecular pathways involved in the disease and adverse events.&lt;h4>Methods&lt;/h4>Two patient populations were included (&lt;i>n&lt;/i> = 89): (i) a study population composed of critically ill COVID-19 and non-COVID-19 patients; (ii) a prospective study cohort composed of COVID-19 survivors and non-survivors among patients assisted by invasive mechanical ventilation (IMV). BAS samples were obtained by bronchoaspiration during the ICU stay. The miRNA profile was analyzed using RT-qPCR. Detai</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021</publication><modification>2025-04-29T10:59:59.824Z</modification><creation>2025-04-06T19:49:49.91Z</creation></dates><accession>S-EPMC8850692</accession><cross_references><pubmed>35186962</pubmed><doi>10.3389/fmed.2021.756517</doi></cross_references></HashMap>